ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "arthritis management and pregnancy"

  • Abstract Number: 2429 • 2018 ACR/ARHP Annual Meeting

    Long-Term Outcome of Children Born to Mothers with Chronic Arthritis and Exposed to TNF-Inhibitors during Pregnancy: A Case-Control Study

    Laura Andreoli1, Maria Chiara Gerardi2, Chiara Bazzani3, Matteo Filippini3, Micaela Fredi2, Roberto Gorla3, Maria Grazia Lazzaroni2, Cecilia Nalli2, Marco Taglietti3, Andrea Lojacono4, Sonia Zatti4, Mario Motta5 and Angela Tincani2, 1Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 3Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, 4Obstetrics and Gynaecology, Spedali Civili and University of Brescia, Brescia, Italy, 5Neonatology and NICU, Spedali Civili of Brescia, Brescia, Italy

    Background/Purpose: Treatment with tumor necrosis factors inhibitors (TNFi) during pregnancy may be required to control maternal disease which can be a threat for maternal-fetal well-being.…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology